专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2009158281A1 CARABINER GLASSES 审中-公开
标题翻译：卡宾玻璃
公开(公告)号：WO2009158281A1
公开(公告)日：2009-12-30
申请号：PCT/US2009/047994
申请日：2009-06-19
申请人： COOPER, Martin, R.
发明人： COOPER, Martin, R.
IPC分类号： G02C5/14
CPC分类号： G02C5/143 , G02C3/00 , G02C11/00
摘要： A frame for glasses includes two temple bars and a lens receiving portion. The temple bar comprises a first end and a second end. The second end of at least one of the temple bars includes a fastening device having a body portion and a closure member, which is configured to move between an open position and a closed position. A temple bar is also provided for herein.
摘要翻译：用于眼镜的框架包括两个镜杆和镜片接收部。寺庙酒吧包括第一端和第二端。至少一个镜腿条的第二端包括具有主体部分和封闭构件的紧固装置，该构件构造成在打开位置和关闭位置之间移动。此处还提供了一个寺庙酒吧。

22. 发明申请

WO2009153569A2 CB1 RECEPTOR MODULATORS 审中-公开
标题翻译： CB1受体调节剂
公开(公告)号：WO2009153569A2
公开(公告)日：2009-12-23
申请号：PCT/GB2009/001539
申请日：2009-06-18
申请人： 7TM PHARMA A/S , MURRAY, Anthony , HOEGBERG, Thomas , COOPER, Martin , BJURLING, Emelie , RECEVEUR, Jean-Marie , NOERREGAARD, Pia, Karina
发明人： MURRAY, Anthony , HOEGBERG, Thomas , COOPER, Martin , BJURLING, Emelie , RECEVEUR, Jean-Marie , NOERREGAARD, Pia, Karina
IPC分类号： C07D401/06 , C07D403/06 , A61K31/4178 , A61P3/04
CPC分类号： C07D401/06 , C07D403/06
摘要： Compounds of formula (I) suppress the normal signalling activity of cannabinoid receptor CB1 and are therefore useful inter alia in the treatment of conditions directly or indirectly associated with obesity and overweight, Wherein A 1 is -COOH or tetrazolyl; R 2 , R 3 , R' 2 and R' 3 are independently selected from -R 9 , - CN, -F, -Cl, -Br, -OR 9 , or -SR 9 ; R 9 is hydrogen, C 1 -C 3 alkyl, cycloalkyl, or fully or partially fluorinated C 1 -C 3 alkyl; R 1 is (i) a bond, or (ii) -C(R 10 )(R 11 )-*, -C(R 10 )(R 11 )-O-*, -C(R 10 )(R 11 )CH 2 -*, Or -CH 2 C(R 10 )(R 11 )-*, wherein the bond indicated by an asterisk is attached to Ring A ring; R 10 is hydrogen and R 11 is hydrogen, (C 1 -C 3 alkyl or -OH; or R 10 and R 11 are both (C 1 -C 3 )alkyl; or R 10 and R 11 taken together with the carbon atom to which they are attached form a (C 3 -C 5 )cycloalkyl ring; Ring A is an aromatic ring as specified ion the claims; Z 1 is a moncyclic group as specified in the claims.
摘要翻译：式（I）化合物抑制大麻素受体CB1的正常信号传导活性，因此特别可用于治疗与肥胖和超重直接或间接相关的病症，其中A1是-COOH或四唑基; R 2，R 3，R'2和R'3独立地选自-R 9，-CN，-F，-Cl，-Br，-OR 9或-SR 9; R9是氢，C1-C3烷基，环烷基或完全或部分氟化的C1-C3烷基; R 1是（i）键或（ii）-C（R 10）（R 11） - *，-C（R 10）（R 11）-O- *，-C（R 10）（R 11）CH 2 - CH2C（R10）（R11） - *，其中由星号表示的键连接到环A环上; R10是氢，R11是氢，（C1-C3烷基或-OH;或R10和R11都是（C1-C3）烷基;或R10和R11与它们所连接的碳原子一起形成（C3-C5 ）环烷基环;环A是权利要求书中规定的芳环; Z1是如权利要求中所指定的单环基团。

23. 发明申请

WO2008051282A2 CRYSTALLINE FORMS OF 4-(2-FLUOROPHENYL)-6-METHYL-2-(PIPERAZIN-1-YL)THIENO(2,3-D)PYRIMIDINE 审中-公开
标题翻译： 4-（2-氟-2-戊烯基）-6-甲基-2-（哌嗪-1-基）噻吩并（2,3-D）吡啶的晶体形式
公开(公告)号：WO2008051282A2
公开(公告)日：2008-05-02
申请号：PCT/US2007/007816
申请日：2007-03-27
申请人： DYNOGEN PHARMACEUTICALS, INC. , COOPER, Martin, Ian , FRAMPTON, Christopher, Stephen
发明人： COOPER, Martin, Ian , FRAMPTON, Christopher, Stephen
IPC分类号： C07D495/04 , A61K31/519 , A61P13/00
CPC分类号： C07D495/04
摘要： The present invention is directed to novel crystalline forms of 4-(2- fluorophenyl)-6-methyl-2-(piperazin-l-yl)thieno[2,3-d]pyrimidine salts, including 4-(2- fluorophenyl)-6-methyl-2-(piperazin-l-yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.
摘要翻译：本发明涉及新的4-（2-氟苯基）-6-甲基-2-（哌嗪-1-基）噻吩并[2,3-d]嘧啶盐的结晶形式，包括4-（2-氟苯基） -6-甲基-2-（哌嗪-1-基）噻吩并[2,3-d]嘧啶盐酸盐结晶形式。本发明还涉及包含这种结晶形式的组合物和用于制备和使用这种结晶形式的方法，例如用于治疗胃肠道和/或泌尿生殖系统疾病。

24. 发明申请

WO2006120470A3 PROCESSOR AND INTERFACE 审中-公开
标题翻译：处理器和接口
公开(公告)号：WO2006120470A3
公开(公告)日：2007-09-07
申请号：PCT/GB2006001756
申请日：2006-05-12
申请人： CAMBRIDGE CONSULTANTS , MORFEY ALISTAIR GUY , SWEPSON KARL LEIGHTON , JOHNSON NEIL EDWARD , COOPER MARTIN DAVID , MYCROFT ALAN
发明人： MORFEY ALISTAIR GUY , SWEPSON KARL LEIGHTON , JOHNSON NEIL EDWARD , COOPER MARTIN DAVID , MYCROFT ALAN
IPC分类号： G06F9/30
CPC分类号： G06F9/3017 , G06F8/4434 , G06F9/30032 , G06F9/30101 , G06F9/30149 , G06F9/30167 , G06F9/30174 , G06F9/30178
摘要： The present invention relates to a processor which comprises an instruction set for execution on the processor, a processor architecture and a memory, wherein the instruction set and the processor architecture comprise characteristics which have been specifically tailored to ensure that the code density compiled for execution at least in part on the processor memory is relatively high. The invention -alsorelates-t?-a compiler.-The-invention-extends to a system comprising a master computer; one or more control pods; and one or more integrated circuits, each comprising one or more processors; wherein the master computer is operable to interact with any of said processors via said one or more control pods.
摘要翻译：本发明涉及一种处理器，其包括用于在处理器上执行的指令集，处理器架构和存储器，其中指令集和处理器架构包括专门定制的特性，以确保编译为执行的代码密度处理器内存最少部分在于相对较高。本发明是一种编译器 - 本发明 - 扩展到包括主计算机的系统; 一个或多个控制舱; 以及一个或多个集成电路，每个集成电路包括一个或多个处理器; 其中所述主计算机可操作以经由所述一个或多个控制盒与任何所述处理器进行交互。

25. 发明申请

WO1990001392A1 MAKING AN ELONGATE CUT USING HIGH ENERGY RADIATION 审中-公开
标题翻译：使用高能量辐射制造直肠切割
公开(公告)号：WO1990001392A1
公开(公告)日：1990-02-22
申请号：PCT/GB1989000942
申请日：1989-08-15
申请人： ANSTALT GERSAN , COOPER, Martin , STEWART, Andrew, David, Garry
发明人： ANSTALT GERSAN
IPC分类号： B23K26/06
CPC分类号： B23K26/364
摘要： To make an elongate cut (1) in a diamond (2) using a laser radiation, a cylindrical optical system (5, 6) is used which converges the radiation at a greater angle of convergence in the plane of the cut (1) than in the transverse plane. In this way, the focal spot energy density is increased and cutting at depth is made more effective.
摘要翻译：为了使用激光辐射在金刚石（2）中制造细长切口（1），使用圆柱形光学系统（5,6），其以较大的会聚角在切割平面（1）中会聚辐射比在横向平面。以这种方式，焦点能量密度增加，深度切割更有效。

26. 发明申请

WO2010132110A1 HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE 审中-公开
标题翻译：（（1S，2S，4R）-4- {4 - [（1S）-2,3-二氢-1H-茚-1-基]氨基] -7H-吡咯并[2,3-D]嘧啶-7-基的盐酸盐 -YL} -2-羟基环戊基）甲磺酸酯
公开(公告)号：WO2010132110A1
公开(公告)日：2010-11-18
申请号：PCT/US2010/001415
申请日：2010-05-13
申请人： MILLENNIUM PHARMACEUTICALS, INC. , ARMITAGE, Ian, G. , CHOPRA, Reenu , COOPER, Martin, Ian , LANGSTON, Marianne
发明人： ARMITAGE, Ian, G. , CHOPRA, Reenu , COOPER, Martin, Ian , LANGSTON, Marianne
IPC分类号： C07D487/04 , A61K31/52 , A61P35/00
CPC分类号： A61K31/519 , C07D487/04 , C07B2200/13
摘要： Disclosed is a compound of formula ( I ); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula ( I ), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula ( I ), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.
摘要翻译：公开了式（I）的化合物; 其结晶形式及其溶剂合物; 药物组合物，其包含药学上有效量的式（I）化合物或其结晶形式，或其溶剂合物和药学上可接受的载体或稀释剂; 以及式（I）化合物或其结晶形式或其溶剂合物用于治疗患有或经受能够通过抑制E1活化酶（特别是NAE）而被改善的病理状况的患者，包括例如癌症。

27. 发明申请

WO2010059239A3 LACTATE SALT OF 4-(6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS 审中-公开
标题翻译： 4-（6-甲氧基-7-（3-哌啶-1-基 - 丙氧基）喹唑啉-4-基]哌嗪-1-羧酸（4-异丙氧基苯基） - 酰胺的乳酸盐及其药物组合物用于治疗癌症和其他疾病或病症
公开(公告)号：WO2010059239A3
公开(公告)日：2010-08-05
申请号：PCT/US2009006235
申请日：2009-11-20
申请人： MILLENNIUM PHARM INC , ARMITAGE IAN , BOURLAND MICHAEL E , BOYLE CRAIG J S , COOPER MARTIN IAN , FERDOUS ABU J , LANGSTON MARIANNE
发明人： ARMITAGE IAN , BOURLAND MICHAEL E , BOYLE CRAIG J S , COOPER MARTIN IAN , FERDOUS ABU J , LANGSTON MARIANNE
IPC分类号： C07D239/94 , A61K31/517 , A61P35/02
CPC分类号： A61K31/517 , C07D239/94
摘要： This invention provides a compound of formula (I): or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thererof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma) glomerulosclerosis, fibrotic disease and inflammation.
摘要翻译：本发明提供了式（I）化合物或其结晶形式，或其药物组合物，或其口服药物剂型; 用于式（I）化合物或其晶体形式或其药物组合物或其口服药物剂型的合成或制造方法; 以及所述化合物或其结晶形式或其药物组合物或其口服药物剂型在治疗患有或遭受涉及细胞存活，增殖和迁移的疾病，病症或病症的患者中的用途包括心血管疾病（例如动脉硬化和血管再阻塞），癌症（例如AML和恶性胶质瘤），肾小球硬化，纤维化疾病和炎症。

28. 发明申请

WO2010059239A2 LACTATE SALT OF 4-(6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS 审中-公开
标题翻译： 4-（6-甲氧基-7-（3-哌啶-1-基 - 丙氧基）喹唑啉-4-基]哌嗪-1-羧酸（4-异丙氧基） - 酰胺及其药物组合物的盐酸盐处理癌症及其他疾病或病症
公开(公告)号：WO2010059239A2
公开(公告)日：2010-05-27
申请号：PCT/US2009/006235
申请日：2009-11-20
申请人： MILLENNIUM PHARMACEUTICALS, INC , ARMITAGE, Ian , BOURLAND, Michael, E. , BOYLE, Craig, J.S. , COOPER, Martin, Ian , FERDOUS, Abu, J. , LANGSTON, Marianne
发明人： ARMITAGE, Ian , BOURLAND, Michael, E. , BOYLE, Craig, J.S. , COOPER, Martin, Ian , FERDOUS, Abu, J. , LANGSTON, Marianne
IPC分类号： C07D239/94 , A61P35/02 , A61K31/517
CPC分类号： A61K31/517 , C07D239/94
摘要： This invention provides a compound of formula (I): or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thererof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma) glomerulosclerosis, fibrotic disease and inflammation.
摘要翻译：本发明提供式（I）化合物或其结晶形式，或其药物组合物，或其口服药物剂型; 用于合成或制备式（I）化合物或其结晶形式或其药物组合物或其口服药物剂型的方法; 以及使用所述化合物或其结晶形式或其药物组合物或其口服药物剂型用于治疗患有或患有涉及细胞存活，增殖和迁移的疾病，病症或病症的患者包括心血管疾病（如动脉硬化和血管重构），癌症（如AML和恶性胶质瘤）肾小球硬化，纤维化疾病和炎症。

29. 发明申请

WO2008075021A1 OPTICAL CORRELATION APPARATUS 审中-公开
标题翻译：光学相关设备
公开(公告)号：WO2008075021A1
公开(公告)日：2008-06-26
申请号：PCT/GB2007/004850
申请日：2007-12-17
申请人： QINETIQ LIMITED , LEWIN, Andrew, Charles , ORCHARD, David, Arthur , COOPER, Martin, James
发明人： LEWIN, Andrew, Charles , ORCHARD, David, Arthur , COOPER, Martin, James
IPC分类号： G06K9/74 , H04Q11/00
CPC分类号： G06K9/74 , G06E3/00 , H04Q11/0005 , H04Q2011/003 , H04Q2011/0032 , H04Q2011/0035
摘要： An optical correlation apparatus is described which forms first and second parallel optical signals in response to a serial input data stream (301). The first parallel optical signal is arranged to have bright pulses represent binary 1 and the second parallel optical signal is arranged to have bright pulses represent binary 0. A channel select means (310a, 310b), such as an optical switch or amplitude modulator, deselects or blocks channels in the first parallel optical signal which correspond to binary 1 in a reference data string and also deselects or blocks channels in the second parallel optical signal which correspond to binary 0 in the reference data string. The remaining optical signals are combined at one or more detectors (312). Where the input data matches the reference data string each bright pulse in the first and second parallel optical signals is deselected and the detector registers zero intensity. However when there is any mismatch at least one channel will pass a bright pulse to the detector. An instance of zero intensity can therefore be used as an indication of pattern match.
摘要翻译：描述了一种响应于串行输入数据流（301）形成第一和第二并行光信号的光学相关装置。第一并行光信号被布置为具有表示二进制1的亮脉冲，并且第二并行光信号被布置为具有表示二进制0的亮脉冲。诸如光开关或振幅调制器的通道选择装置（310a，310b）取消选择或者在对应于参考数据串中的二进制1的第一并行光信号中阻塞通道，并且还取消选择或阻止在参考数据串中对应于二进制0的第二并行光信号中的通道。剩余的光信号在一个或多个检测器（312）处组合。在输入数据与参考数据串匹配的情况下，取消选择第一和第二并行光信号中的每个亮脉冲，并且检测器记录零强度。然而，当存在任何失配时，至少一个通道将通过明亮的脉冲到检测器。因此，零强度的实例可以用作模式匹配的指示。

30. 发明申请

WO2008074982A1 PYRAZOLE DERIVATIVES AS MODULATORS OF CANNABINOID RECEPTOR 审中-公开
标题翻译：作为CANNABINOID受体调节剂的吡唑衍生物
公开(公告)号：WO2008074982A1
公开(公告)日：2008-06-26
申请号：PCT/GB2007/004703
申请日：2007-12-10
申请人： 7TM PHARMA A/S , COOPER, Martin , RECEVEUR, Jean-Marie , HOEGBERG, Thomas , NIELSEN, Peter, Aadal , LINGET, Jean-Michel , NOEREGAARD, Pia, Karina
发明人： COOPER, Martin , RECEVEUR, Jean-Marie , HOEGBERG, Thomas , NIELSEN, Peter, Aadal , LINGET, Jean-Michel , NOEREGAARD, Pia, Karina
IPC分类号： A61K31/4155 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , A61P3/04
CPC分类号： C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04
摘要： Compounds of formula (I) suppress the normal signalling activity of CB1 receptors, and are useful in the treatment of, for example obesity or overweight formula (I): wherein A 1 , A 2 , A 5 , A 6 , R 1 , R 2 , R 3 , and X are as defined in the claims.
摘要翻译：式（I）化合物抑制CB1受体的正常信号传导活性，并且可用于治疗例如肥胖或超重配方（I）：其中A 1，A 2， A 5，A 6，R 1，R 2，R 3， / SUB，和X如权利要求中所定义。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式